Seer Sees $55 Million in the Bank
Seer, a San Francisco based life sciences company capturing insights from the proteome, announced a $55 million Series D round led by aMoon Fund. This funding comes one year after Seer announced their $36 million venture round to come out of stealth, and brings total funding to over $100 million.
Seer uses high-speed, high-accuracy proteomic analysis with their Proteograph‚Ñ¢ platform to enable insights and understanding of biology and diseases. The resulting data complements genomic and other health data to answer clinical challenges, such as disease detection at early stages. Seer’s second patent application was also published recently.
Related Posts
Cala Health Claims to Have the only Patented Neurostimulation for Essential Tremor Treatment. The Patent Data Disagrees
Cala Health has figured out that innovations backed by patents make them exponentially more valuable in the marketplace. However, in a zest…
Capital One is Investing in AI Biotech? What’s in their wallet?
In the past 18 months, Capital One has expanded past its usual banking activities, and begun exploring the AI Biotech Sector. But do they…
Google AI Reinvents Speech Recognition. Who will follow?
There is no doubt that the big 5 tech companies (Apple, Amazon, Google, Facebook, and Microsoft) have developed massive IP portfolios in…